It takes lots of fresh ingredients to cook up a successful marketing agency. Talent. Relationships. Courage. A positive culture. Strong, committed leadership. Mentorship. Strategic vision. A willingness to innovate. The ability to stay awake for 48 consecutive hours. And plenty more. One other ingredient, though, doesn’t often get the attention that we feel it should. It may in fact be just as critical as all the others to an agency’s long-term success, but by its nature can often sink into the background. Social responsibility.
Side effects may include generalized paragraph counting, occasional moral discomfort, reference anxiety, and recurring dreams of side effect reels on loop.
John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company, will retire as president and CEO and from the company effective Dec. 31, 2016.
Grünenthal Group named Gabriel Baertschi to become the company’s new CEO as of Oct. 1, 2016.
Alicia Secor has been named president and CEO of Juniper Pharmaceuticals Inc., effective Aug. 1, 2016. Secor will also be appointed to the board of directors.
Dave Sheehan has joined ContextMedia:Health as chief marketing officer.
Grey Doyle is appointed CEO of Leading BioSciences Inc. Doyle, a long-standing member of Leading BioSciences’ executive management team and board of directors, previously served as chief operations officer and chief financial officer.
Glenn Nedwin, Ph.D., has become CEO, president, and member of the board of directors of Second Genome Inc.
The latest innovation in oncology research is tying tumor biomarkers to specific treatments in order to improve patient outcomes. Med Ad News spoke with Gerald Messerschmidt, M.D., chief medical officer of Precision Oncology, to find out how the biomarker-treatment link will help get treatments to market, and to the right patients, faster.